<p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - 获取免费报告) 周三的期权交易异常活跃。股票投资者购买了 25,745 份该公司的看涨期权。这比平均交易量 6,521 份看涨期权增加了 295%。</p>
<p>获取 <strong>Reviva Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师升级和降级</h2>
<p>RVPH 已成为多份研究报告的主题。D. Boral Capital 在周二的报告中重申了对 Reviva Pharmaceuticals 的 &#34;买入&#34; 评级，并设定了 2.00 美元的目标价。Benchmark 在 9 月 15 日的研究报告中将 Reviva Pharmaceuticals 的目标价从 14.00 美元下调至 7.00 美元，并对该股票设定了 &#34;投机性买入&#34; 评级。HC Wainwright 在 10 月 27 日的报告中将 Reviva Pharmaceuticals 的目标价从 11.00 美元下调至 4.00 美元，并对该股票设定了 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Reviva Pharmaceuticals 的 &#34;卖出 (e+)&#34; 评级。最后，Wall Street Zen 在 10 月 4 日的研究报告中将 Reviva Pharmaceuticals 的评级上调至 &#34;卖出&#34;。一位投资分析师对该股票给予了强烈买入评级，七位分析师给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 3.86 美元。</p>
<p><strong>获取我们对 RVPH 的最新分析</strong></p>
<h2>Reviva Pharmaceuticals 股价下跌 45.5%</h2>
<p>NASDAQ RVPH 周三开盘价为 0.32 美元。该股票的 50 日移动平均线为 0.57 美元，200 日移动平均线为 0.52 美元。该公司的市值为 3697 万美元，市盈率为 -0.70，贝塔值为 -0.02。Reviva Pharmaceuticals 的一年低点为 0.25 美元，一年高点为 2.17 美元。</p>
<p>Reviva Pharmaceuticals (NASDAQ:RVPH - 获取免费报告) 最近于 11 月 13 日发布了季度财报。该公司报告每股收益为（0.06）美元，超出市场共识预期的（0.11）美元 0.05 美元。作为一个整体，股票研究分析师预测 Reviva Pharmaceuticals 本财年的每股收益将为 -0.97 美元。</p>
<h2>Reviva Pharmaceuticals 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近对 RVPH 的持仓进行了调整。Armistice Capital LLC 在第二季度购买了价值约 1,026,000 美元的 Reviva Pharmaceuticals 新头寸。683 Capital Management LLC 在第二季度购买了价值 381,000 美元的 Reviva Pharmaceuticals 新股份。Persistent Asset Partners Ltd 在第二季度将其在 Reviva Pharmaceuticals 的持仓增加了 300.0%。Persistent Asset Partners Ltd 现在拥有 641,174 股该公司的股票，价值 244,000 美元，此前在上个季度又购买了 480,864 股。Millennium Management LLC 在第三季度将其在 Reviva Pharmaceuticals 的持仓增加了 15.0%。Millennium Management LLC 现在拥有 1,711,221 股该公司的股票，价值 631,000 美元，此前在此期间又收购了 223,178 股。最后，Lido Advisors LLC 在第三季度购买了价值 37,000 美元的 Reviva Pharmaceuticals 新股份。对冲基金和其他机构投资者持有该公司 63.18% 的股份。</p>
<h2>Reviva Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Reviva Pharmaceuticals, Inc NASDAQ: RVPH 是一家专注于在美国和部分国际市场收购、开发和商业化处方药产品的专业制药公司。公司成立于 2002 年，总部位于佛罗里达州科勒尔盖布尔斯，Reviva 主要针对那些未被充分推广的、已过专利期的药物，这些药物的新剂型可以提高患者的依从性和治疗效果。</p>
<p>公司的核心活动包括识别 FDA 批准的药物候选者，开发配方以满足特定或服务不足的患者群体——例如儿科和孤儿适应症——并支持监管申请。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Reviva Pharmaceuticals</li>
<li>可能每月带来高达 4,290 美元的无聊 AI 投资</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Reviva Pharmaceuticals 吗？</h2>
<p>在你考虑 Reviva Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Reviva Pharmaceuticals 并不在名单上。</p>
<p>虽然 Reviva Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

RVPH

<p>Reviva Pharmaceuticals（纳斯达克代码：RVPH）的看涨期权交易量增加了 295%，共购入 25,745 份期权，而平均交易量为 6,521 份。分析师的评级意见不一，普遍共识为 “适度买入”，目标价为 3.86 美元。该股票开盘价为 0.32 美元，下跌 45.5%，市值为 3697 万美元。机构投资者持有 63.18% 的股份</p>

<p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 25,745 call options on the company. This is an increase of 295% compared to the average volume of 6,521 call options.</p>
<div class="lb-trans"><p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - 获取免费报告) 周三的期权交易异常活跃。股票投资者购买了 25,745 份该公司的看涨期权。这比平均交易量 6,521 份看涨期权增加了 295%。</p>
</div><p>Get <strong>Reviva Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Reviva Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>RVPH has been the topic of a number of research reports. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $2.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday. Benchmark dropped their price target on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a &#34;speculative buy&#34; rating on the stock in a research note on Monday, September 15th. HC Wainwright lowered their target price on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, October 27th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Reviva Pharmaceuticals to a &#34;sell&#34; rating in a research note on Saturday, October 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $3.86.</p>
<div class="lb-trans"><p>RVPH 已成为多份研究报告的主题。D. Boral Capital 在周二的报告中重申了对 Reviva Pharmaceuticals 的 &#34;买入&#34; 评级，并设定了 2.00 美元的目标价。Benchmark 在 9 月 15 日的研究报告中将 Reviva Pharmaceuticals 的目标价从 14.00 美元下调至 7.00 美元，并对该股票设定了 &#34;投机性买入&#34; 评级。HC Wainwright 在 10 月 27 日的报告中将 Reviva Pharmaceuticals 的目标价从 11.00 美元下调至 4.00 美元，并对该股票设定了 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Reviva Pharmaceuticals 的 &#34;卖出 (e+)&#34; 评级。最后，Wall Street Zen 在 10 月 4 日的研究报告中将 Reviva Pharmaceuticals 的评级上调至 &#34;卖出&#34;。一位投资分析师对该股票给予了强烈买入评级，七位分析师给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 3.86 美元。</p>
</div><p><strong>Get Our Latest Analysis on RVPH</strong></p>
<div class="lb-trans"><p><strong>获取我们对 RVPH 的最新分析</strong></p>
</div><h2>Reviva Pharmaceuticals Trading Down 45.5%</h2>
<div class="lb-trans"><h2>Reviva Pharmaceuticals 股价下跌 45.5%</h2>
</div><p>NASDAQ RVPH opened at $0.32 on Wednesday. The stock has a 50-day moving average of $0.57 and a 200-day moving average of $0.52. The firm has a market cap of $36.97 million, a PE ratio of -0.70 and a beta of -0.02. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $2.17.</p>
<div class="lb-trans"><p>NASDAQ RVPH 周三开盘价为 0.32 美元。该股票的 50 日移动平均线为 0.57 美元，200 日移动平均线为 0.52 美元。该公司的市值为 3697 万美元，市盈率为 -0.70，贝塔值为 -0.02。Reviva Pharmaceuticals 的一年低点为 0.25 美元，一年高点为 2.17 美元。</p>
</div><p>Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. As a group, equities research analysts forecast that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Reviva Pharmaceuticals (NASDAQ:RVPH - 获取免费报告) 最近于 11 月 13 日发布了季度财报。该公司报告每股收益为（0.06）美元，超出市场共识预期的（0.11）美元 0.05 美元。作为一个整体，股票研究分析师预测 Reviva Pharmaceuticals 本财年的每股收益将为 -0.97 美元。</p>
</div><h2>Institutional Trading of Reviva Pharmaceuticals</h2>
<div class="lb-trans"><h2>Reviva Pharmaceuticals 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in RVPH. Armistice Capital LLC bought a new position in Reviva Pharmaceuticals during the second quarter valued at approximately $1,026,000. 683 Capital Management LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter worth $381,000. Persistent Asset Partners Ltd increased its position in Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company's stock worth $244,000 after buying an additional 480,864 shares in the last quarter. Millennium Management LLC raised its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company's stock worth $631,000 after acquiring an additional 223,178 shares during the period. Finally, Lido Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 63.18% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 RVPH 的持仓进行了调整。Armistice Capital LLC 在第二季度购买了价值约 1,026,000 美元的 Reviva Pharmaceuticals 新头寸。683 Capital Management LLC 在第二季度购买了价值 381,000 美元的 Reviva Pharmaceuticals 新股份。Persistent Asset Partners Ltd 在第二季度将其在 Reviva Pharmaceuticals 的持仓增加了 300.0%。Persistent Asset Partners Ltd 现在拥有 641,174 股该公司的股票，价值 244,000 美元，此前在上个季度又购买了 480,864 股。Millennium Management LLC 在第三季度将其在 Reviva Pharmaceuticals 的持仓增加了 15.0%。Millennium Management LLC 现在拥有 1,711,221 股该公司的股票，价值 631,000 美元，此前在此期间又收购了 223,178 股。最后，Lido Advisors LLC 在第三季度购买了价值 37,000 美元的 Reviva Pharmaceuticals 新股份。对冲基金和其他机构投资者持有该公司 63.18% 的股份。</p>
</div><h2>Reviva Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Reviva Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Reviva Pharmaceuticals, Inc NASDAQ: RVPH is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.</p>
<div class="lb-trans"><p>Reviva Pharmaceuticals, Inc NASDAQ: RVPH 是一家专注于在美国和部分国际市场收购、开发和商业化处方药产品的专业制药公司。公司成立于 2002 年，总部位于佛罗里达州科勒尔盖布尔斯，Reviva 主要针对那些未被充分推广的、已过专利期的药物，这些药物的新剂型可以提高患者的依从性和治疗效果。</p>
</div><p>The company's core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.</p>
<div class="lb-trans"><p>公司的核心活动包括识别 FDA 批准的药物候选者，开发配方以满足特定或服务不足的患者群体——例如儿科和孤儿适应症——并支持监管申请。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Reviva Pharmaceuticals</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>A month before the crash</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Reviva Pharmaceuticals</li>
<li>可能每月带来高达 4,290 美元的无聊 AI 投资</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Reviva Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Reviva Pharmaceuticals 吗？</h2>
</div><p>Before you consider Reviva Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Reviva Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Reviva Pharmaceuticals 并不在名单上。</p>
</div><p>While Reviva Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Reviva Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

投资者大量购买 Reviva Pharmaceuticals（NASDAQ:RVPH）的看涨期权